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Abstract
Background: Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are
two highly homologous neuropeptides. In vitro and ex vivo experiments repeatedly demonstrate that these
peptides exert pronounced immunomodulatory (primarily anti-inflammatory) actions which are mediated by
common VPAC1 and VPAC2 G protein-coupled receptors. In agreement, we have shown that mice deficient in
PACAP ligand or VPAC2 receptors exhibit exacerbated experimental autoimmune encephalomyelitis (EAE). However,
we observed that VIP-deficient mice are unexpectedly resistant to EAE, suggesting a requirement for this peptide at
some stage of disease development. Here, we investigated the involvement of VPAC1 in the development of EAE
using a VPAC1-deficient mouse model.
Methods: EAE was induced in wild-type (WT) and VPAC1 knockout (KO) mice using myelin oligodendrocyte
glycoprotein 35–55 (MOG35–55), and clinical scores were assessed continuously over 30 days. Immune responses in
the spinal cords were determined by histology, real-time PCR and immunofluorescence, and in the draining lymph
nodes by antigen-recall assays. The contribution of VPAC1 expression in the immune system to the development of
EAE was evaluated by means of adoptive transfer and bone marrow chimera experiments. In other experiments,
VPAC1 receptor analogs were given to WT mice.
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Results: MOG35–55-induced EAE was ameliorated in VPAC1 KO mice compared to WT mice. The EAE-resistant
phenotype of VPAC1 KO mice correlated with reduced central nervous system (CNS) histopathology and cytokine
expression in the spinal cord. The immunization phase of EAE appeared to be unimpaired because lymph node
cells from EAE-induced VPAC1 KO mice stimulated in vitro with MOG exhibited robust proliferative and Th1/Th17
responses. Moreover, lymph node and spleen cells from KO mice were fully capable of inducing EAE upon transfer
to WT recipients. In contrast, WT cells from MOG-immunized mice did not transfer the disease when administered
to VPAC1 KO recipients, implicating a defect in the effector phase of the disease. Bone marrow chimera studies
suggested that the resistance of VPAC1-deficient mice was only minimally dependent on the expression of this
receptor in the immunogenic/hematopoietic compartment. Consistent with this, impaired spinal cord inductions of
several chemokine mRNAs were observed in VPAC1 KO mice. Finally, treatment of WT mice with the VPAC1
receptor antagonist PG97-269 before, but not after, EAE induction mimicked the clinical phenotype of VPAC1 KO
mice.
Conclusions: VPAC1 gene loss impairs the development of EAE in part by preventing an upregulation of CNS
chemokines and invasion of inflammatory cells into the CNS. Use of VPAC1 antagonists in WT mice prior to EAE
induction also support a critical role for VPAC1 signaling for the development of EAE.
Keywords: Multiple sclerosis, Experimental autoimmune encephalomyelitis, Neuropeptide, VPAC1,
Neuroimmunomodulation
Background
Vasoactive intestinal peptide (VIP) and pituitary adenyl-
ate cyclase-activating polypeptide (PACAP) are two
highly homologous neuropeptides of the secretin/gluca-
gon superfamily [1, 2]. They act through three class II G
protein-coupled receptors (GPCRs) officially named by
International Union of Basic and Clinical Pharmacology
(IUPHAR) as VPAC1, VPAC2, and PAC1 [3]. Whereas
VPAC1 and VPAC2 bind either peptide with equally
high affinity, PAC1 is known to be a PACAP-preferring
receptor. Signaling through these receptors mainly in-
volves the Gαs protein and leads to activation of adenylyl
cyclase and cAMP production [1]. However, they can also
increase inositol triphosphate and intracellular calcium
levels through the phospholipase C pathway as well as
modulate the activity of phospholipase D, tyrosine kinases,
and calcium and potassium channels [1].
Multiple studies in the early 1990s reported the expres-
sion of VIP, PACAP, and their receptors in the immune
system and were followed up by the discovery of their
immunomodulatory properties through a direct action on
diverse immune cell subtypes such as T lymphocytes,
macrophages, and dendritic cells [4]. These cells constitu-
tively express VPAC1. VPAC2 expression, on the other
hand, is very low in resting lymphocytes and macrophages
but strongly induced in macrophages after exposure to
stimuli such as lipopolysaccharide (LPS), the major
component of the outer membrane of Gram-negative
bacteria, and in lymphocytes activated with an anti-
CD3 antibody [5, 6]. In addition, constitutive expression
of VPAC2 in dendritic cells and of PAC1 in macrophages
has been reported [7, 8].
VIP and PACAP modulate multiple aspects of immun-
ity, and notably, they are potent anti-inflammatory
peptides [4]. In this regard, initial in vitro studies
described that VIP and PACAP strongly inhibited the
production of a wide range of pro-inflammatory cyto-
kines and chemokines by macrophages stimulated with
LPS but stimulated the production of anti-inflammatory
cytokines such as interleukin (IL)-10 [9–11]. The effi-
cient blockade of the inflammatory response by these
peptides appears to be mediated by their inhibitory
action on key signaling pathways common to the expres-
sion of several cytokines, notably NF-kB and MAPK
[12]. Besides VIP and PACAP actions on innate immun-
ity, other in vitro studies demonstrated that they modu-
late adaptive immune responses by acting on T helper
(Th) differentiation [13, 14]. In concurrence with their
generally anti-inflammatory actions, it was found that
VIP and PACAP inhibit Th1 and potentiate Th2 responses.
This was demonstrated to be mediated at least in part by
actions on dendritic cell co-stimulatory molecules and
cytokine/chemokine production [7, 11, 15–17]. Similarly,
human plasmacytoid dendritic cells activated with CpG
oligonucleotides stimulate CD4+ T cell proliferation and
cytokine production ex vivo. The addition of VIP during
dendritic cell activation resulted in decreased interferon
(IFN)γ production and CD4+ Tcell proliferation, generating
a Th2-like response [18]. Other in vitro and in vivo
studies have suggested that VIP and PACAP directly
promote specific Th2 cell survival and Th2 memory
cell generation [19–21].
More recent studies have demonstrated the ability of
these peptides to induce regulatory T cells (Tregs) [22–27].
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Due to their anti-inflammatory actions on innate and
adaptive immune function, VIP and PACAP adminis-
tration reduced clinical symptoms and pathological
changes in murine models of several inflammatory and
Th1-driven autoimmune conditions, including rheuma-
toid arthritis, Crohn’s disease, and multiple sclerosis
(MS) [28–30].
We recently began to examine the relevance of the
endogenous neuropeptides and the role of receptor
subtypes by gene deletion in the murine model of
experimental autoimmune encephalomyelitis (EAE), a
widely used model for MS [31]. MS, the most common
neurodegenerative condition in young adults, is a chronic
and inflammatory demyelinating disease of the central
nervous system (CNS) [32]. Despite its complex pathogen-
esis, considerable evidence suggests that autoimmune cells
reacting against myelin peptides play a major role in the
initiation and development of the disease. In fact, EAE is
induced by immunizing mice with myelin peptides in
order to generate encephalitogenic T cells in the prox-
imal lymph nodes. Both IFNγ-producing Th1 and IL-
17-producing Th17 pro-inflammatory cells have been
implicated in the pathogenesis of EAE. These T cells
migrate into the CNS where, once reactivated, they
initiate an inflammatory cascade. We have previously
found that PACAP- or VPAC2-targeted gene deletions
in mice lead to exacerbated disease, supporting the
anti-inflammatory properties of PACAP and VPAC2
[33]. However, we unexpectedly found that VIP kno-
ckout (KO) mice developed ameliorated EAE and
reduced inflammation in models of LPS-induced endotox-
emia and chemically-induced colitis [34–36]. A critical
question to be addressed is which VIP receptor medi-
ates this paradoxical resistance to inflammation. Here,
we have examined the relevance of VPAC1 in auto-
immune CNS inflammation by subjecting VPAC1-
deficient mice to EAE.
Methods
Mice
Eight to 12-week-old female C57BL/6 (wild-type (WT))
and VPAC1 KO mice [37] were used. Mice were
maintained in specific pathogen-free barrier facilities
at the University of California, Los Angeles (UCLA).
All husbandry and experimental procedures were per-
formed in compliance with the USDA Animal Wel-
fare Act regulations section 2.31(d)(5), Institutional
Policies and Guidelines, and adhered to all principles
stated in the Guide for the Care and Use of Labora-
tory Animals. The experimental protocol was ap-
proved by the UCLA Animal Resource Committee
(ARC# 1993-302). VPAC1 KO mice were fed gruel
every day starting after weaning on postnatal day 35
to avoid intestinal dysfunction.
EAE induction
EAE was induced as previously described [38]. Briefly,
mice were lightly anesthetized with isoflurane, and a so-
lution containing 100 μg of MOG35–55 (GLBiochem) in
complete Freund’s adjuvant (Difco) supplemented with
5 mg/ml Mycobacterium tuberculosis H37Ra (Difco) was
injected subcutaneously in the flanks. Two hundred
nanograms of Pertussis toxin (List Biological Laborator-
ies) was administered intraperitoneally (i.p.) to the mice
on the immunization day as well as 2 days later. For
VPAC1 antagonist pretreatment studies, WT mice were
given i.p. either PBS or 10 nmol of the VPAC1 antagon-
ist PG97-269 [39] daily for 2 weeks. Two days after the
last dose of the VPAC1 antagonist, EAE was induced as
above. For antagonist/agonist treatment studies during
ongoing EAE, the VPAC1 antagonist PG97-269 at
10 nmol per mouse or the VPAC1 agonist (Ala11, 22, 28)VIP
at 5 nmol per mouse were administered i.p. for five
consecutive days starting on day 3 after mice immunization
with MOG. EAE symptoms were scored daily on a
0–4 scale as follows: 0, no symptoms; 1, wobbling
gait; 2, hind leg paralysis; 3, paralysis of two limbs;
and 4, moribund or dead.
Histopathology
The spinal cords were collected 30 days after EAE
induction, fixed in 4 % PFA overnight and then gradually
dehydrated in ethanol until paraffin embedding. Six-
micrometer sections were prepared with a microtome
and stained with luxol fast blue (for myelin) and
hematoxylin-eosin (for stroma and immune infiltrates)
following standard protocols. Histopathology was scored
as follows: 0, normal appearance of tissue; 1, scarce
immune cell infiltration and demyelination; 2, perivascu-
lar infiltrates with a few areas of demyelination; and 3,
increasing severity of perivascular cuffing with extension
into adjacent tissue and large areas of demyelination.
Immunofluorescence
Fourteen days after EAE induction, mice were perfused
with 4 % PFA and the spinal cords were collected, post-
fixed overnight, and cryoprotected with a 20 % sucrose
solution. Cryostat 15-μm sections were prepared and
incubated with anti-CD4 (BD Pharmingen) and anti-
laminin (Sigma-Aldrich) antibodies in PBS/1 % bovine
serum albumin (BSA)/0.3 % Triton X-100 at 4 °C
overnight. Then, sections were incubated for 40 min at
room temperature with Alexa 594- and FITC-conjugated
secondary antibodies. Slides were mounted using VEC-
TASHIELD with DAPI (Vector Labs).
Real-time RT-PCR
The brain and spinal cords were collected on day 5, at
the clinical peak (days 14–15) or 30 days post-EAE
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induction and mechanically homogenized in Trizol (Sigma-
Aldrich). RNA was extracted according to the manufac-
turer’s instructions. Before cDNA synthesis, RNA samples
were treated with DNase I (DNA-free kit, Ambion) accord-
ing to the manufacturer’s protocol. One micrograms of
total RNA was reverse-transcribed using the iScript
kit from Bio-Rad (Hercules). Quantitative real-time
RT-PCR for the cytokines tumor necrosis factor
(TNF)α, IFNγ, IL-4, IL-6, IL-10, IL-17, and IL-23p19;
the chemokines regulated on activation, normal T cell
expressed and secreted (RANTES)/CCL5, monocyte
chemoattractant protein (MCP)-1/CCL2, MCP-2/
CCL8, monokine induced by gamma interferon (MIG)/
CXCL9, interferon gamma-induced protein 10 (IP-10)/
CXCL10, and MIP-3α/CCL20; the chemokine recep-
tors, CCR1, CCR2, and CCR5; the adhesion molecules
intercellular adhesion molecule (ICAM) and vascular
cell adhesion molecule (VCAM); and the transcription
factor Foxp3 was performed using the iQ SYBR Green
Supermix from Bio-Rad. Primers and real-time PCR
conditions are described in the Additional file 1: Table
S1. For relative quantification, the relative expression
was determined by the 2−ΔΔCt method (Ct denoting the
threshold cycle of PCR amplification at which product
is first detected by fluorescence), which compares the
amount of target gene amplification, normalized to the
hypoxanthine-guanine phosphoribosyltransferase (HPRT)
endogenous reference [40]. Melting curves estab-
lished the purity of the amplified band. For each
probe set, PCR products were sequenced to confirm
identity.
Ex vivo studies
Axillary lymph nodes were collected 14 days after
EAE induction and cell suspensions prepared by tap-
ping the organs through a 40-μm nylon mesh. Cells
were cultured at 1 × 106 cells/ml in 96-well plates in
complete RPMI 1640 (25 mM HEPES, 2 mM L-glu-
tamine, 1 % penicillin/streptomycin, and 2 % FBS), in
the presence of MOG or ovalbumin (OVA) at 10 μg/
ml. For measurement of cytokines (IFNγ, IL-17A, IL-
10), supernatants were collected 48 h later and stored
at −20 °C until analysis by ELISA, using antibody kits
from PeproTech and eBioscience following manufac-
turer’s instructions. Because the levels of IL-4 pro-
tein were below the detection threshold by ELISA,
we determined the expression of this cytokine by
real-time RT-PCR. Thus, cells were also collected
for RNA extraction with Trizol after the 48-h re-
stimulation period. In order to assess cell prolifera-
tion, [3H]-thymidine (1 μCi/well) was added after
2 days of culture for 18 additional hours, and in-
corporated radioactivity was measured on a β-
scintillation counter (Beckman).
Adoptive transfer
The lymph node and spleen cells were collected from
EAE-induced WT and VPAC1 KO mice on day 12 and
restimulated in vitro at 1.5 × 106 or 3 × 106 cells/ml,
respectively, in complete RPMI with 30 μg/mL of
MOG35–55. Three days later, cells (5 × 10
6 splenocytes
and 5 × 106 lymph node cells) were intravenuosly (i.v.)
injected into naïve WT or VPAC1 KO recipients. Mice also
received 200 ng of pertussis toxin i.p. on days 0 and 2, and
clinical symptoms of EAE were scored on a daily basis.
Bone marrow chimeras
C57BL/6 WT mice were γ-irradiated at 4–6 weeks of
age with 550 rads twice with a gap of 2 h to deplete BM
immune hematopoietic elements. Following irradiation,
mice were provided antibiotics (neomycin sulfate 2 mg/
ml) for 2 weeks. Four hours after irradiation, 107 BM
cells from either VPAC1 KO (CD45.2) or WT (CD45.2)
mice (isolated by flushing the femur with a needle and
syringe) were intravenously infused to irradiated mice
(CD45.1). The percent donor composition was deter-
mined by measuring the percentage of CD45.2 (donor)
vs. CD45.1 (recipient) in whole blood cells in the
recipient mice before EAE induction. Mice were main-
tained in quarantine for 6 weeks before EAE induction
as above.
Statistical analysis
Differences between groups were evaluated using GraphPad
Prism 6 software (GraphPad Software, San Diego,
CA) and Student’s t test with Welch’s correction. The
level of significance was set at P < 0.05. Results are
expressed as mean ± SEM.
Results
VPAC1 KO mice exhibit reduced clinical and
histopathological features of EAE
In order to investigate the role of the VPAC1 receptor in
the development of EAE, we immunized WT and
VPAC1 KO mice with MOG35–55 and monitored the
appearance of clinical symptoms of the disease on a daily
basis. We found that EAE clinical symptoms were
significantly ameliorated in VPAC1 KO mice. A curve
representing the summation of three experiments is
shown on Fig. 1a. Indeed, they exhibited lower average
cumulative scores (11.2 ± 2.7 vs 25.5 ± 3.4, **p < 0.01)
compared to WT mice (calculated as the average sum of
all EAE clinical scores in a diseased mouse). In addition,
the onset of the disease was delayed in those VPAC1
KO mice who developed EAE (KO average onset of
19.7 ± 1.5 vs 10.5 ± 0.4 days in WT mice, ***p < 0.001).
Overall, in the total of three experiments, the inci-
dence of the disease was 50 % for VPAC1 KO mice
(9 mice out of 18 developed EAE symptoms) vs. 84 %
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for WT mice (15 out of 18). To mimic the effect of genetic
loss of VPAC1, WT mice were treated with the VPAC1
receptor-specific antagonist (PG97-269 [22]) for 2 weeks
prior to EAE immunization. This pretreatment led to a
reduced clinical EAE similar to VPAC1 KO mice, although
no delay in the onset of the disease was observed (Fig. 1b).
These data suggest a critical requirement of the VPAC1
receptor for the development of the full disease. Interest-
ingly, treatment of WT mice with a VPAC1 antagonist for
5 days starting on day 3 post-EAE induction did not block
EAE development (Additional file 2: Figure S1), suggesting
that either the absence of VPAC1 signaling before disease
induction or a long-term blockade of signaling through
this receptor is necessary to impede the full development
of EAE. Moreover, a short-term treatment with the
VPAC1 agonist starting on day 3 post-immunization
prevented the development of EAE (Additional file 2:
Figure S1), in agreement with the anti-inflammatory
activities of VIP.
In accordance with the reduced clinical disease, the
spinal cords of VPAC1 KO mice exhibited minor im-
mune cell infiltration as well as reduced demyelination
compared to WT mice 30 days after the induction of
the disease, as reflected in the average histological
scores (0.6 ± 0.1 in VPAC1 KO vs 1.6 ± 0.1 in WT mice,
***p < 0.001, Fig. 1c) and representative micrographs
(Fig. 1d, e). Furthermore, corroborating their lower
degree of inflammation in the CNS, we found a gener-
alized lower expression of pro-inflammatory and anti-
inflammatory cytokines in the CNS of VPAC1 KO vs.
WT mice (TNFα, IL-6, IFNγ, IL-17, IL23p19, IL-4, and
IL-10, Fig. 2), as determined on day 30 by real-time
PCR. A reduction in the mRNA expression of Foxp3, a
transcription factor that specifically marks Tregs, was
also observed in the spinal cords of the KO mice. These
results show a limited clinical response of VPAC1 KO
mice to EAE induction, associated with a reduced
immunological response in the CNS.
Fig. 1 Reduced clinical EAE and histopathology in VPAC1 KO vs. WT mice. EAE was induced by immunizing mice subcutaneously with 100 μg of
MOG35–55 in CFA supplemented with Mycobacterium tuberculosis. EAE clinical scores were monitored daily on a scale of 0 to 4 as described in the
“Methods” section. Spinal cord microsections were stained with luxol fast blue (for demyelination) and hematoxylin-eosin (for immune cell
infiltration), and histopathology was scored from 0 to 3 as described in the “Methods” section. a Clinical curve displaying mean clinical
scores ± SEM of immunized WT vs. VPAC1 KO mice, representing the summation of three experiments (n = 18 mice per genotype). b Clinical
curve displaying mean clinical scores ± SEM of immunized WT mice pretreated with PBS or a VPAC1 antagonist, representing the summation of
two experiments (n = 15 for WT-PBS and n = 11 for WT-VPAC1 antagonist). c Mean histopathological score at day 30 of three experiments ± SEM
(n = 12 in each group). ***p < 0.001 Student’s t test. ND = not determined. d Low- (×4) and e high- (×20) magnification photomicrographs of day
30 WT and VPAC1 KO mice transverse thoracolumbar spinal cord sections
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VPAC1 KO mice exhibit robust Th1 and Th17 cell
responses against MOG despite the lack of clinical EAE
The lack of EAE in VPAC1-deficient mice could be due to
a defect in MOG immunization. To test this hypothesis, we
performed antigen-recall assays in which responses to
MOG were examined in cultured lymph node cells isolated
from WT or VPAC1 KO mice 14 days after EAE induction.
We found that both WT- and VPAC1-deficient mice cells
exhibited robust proliferation and production of IFNγ
(Th1) and IL-17 (Th17) when stimulated with MOG but
not with an irrelevant antigen (OVA) (Fig. 3). More-
over, these were significantly stronger in KO than in
Fig. 2 Cytokine expression in the CNS of EAE-immunized mice is reduced in VPAC1 KO mice. EAE was induced in WT- and VPAC1-deficient mice,
and the spinal cords were collected and fresh-frozen in liquid nitrogen 30 days later. RNA was extracted and retrotranscribed to cDNA, and the
levels of expression of TNFα, IL-6, IFNγ, IL-17, IL-23p19, IL-4, IL-10, and Foxp3 determined by real-time RT-PCR as described in the “Methods”
sections. Results shown are representative of three independent experiments of n = 8 mice/group. *p < 0.05, **p < 0.01, ***p < 0.001, ns = not
significant; Student’s t test
Fig. 3 Antigen-recall assay demonstrates robust responses to MOG of lymph node cells from either WT or VPAC1 KO mice after EAE immunization.
EAE was induced to WT and VPAC1 KO mice and draining lymph nodes were isolated at the peak of the WT disease (day 14). Cells were cultured for
48 h at 1 × 106 cells/ml in 96-well plates in the presence of OVA or MOG (10 μg/ml). a Proliferation determined by measurement of [3H]-thymidine
incorporation. b Cytokine responses in WT vs. VPAC1 KO lymph node cultures. The levels of IFNγ (Th1), IL-17 (Th17), and IL-10 (Th2/Treg) were
measured in the supernatants by ELISA. The expression of IL-4 mRNA in the cultured cells was determined by real-time RT-PCR. Results shown are
representative of three independent experiments of n = 8 mice/group. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test
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WT cultures, suggesting exacerbated Th1 and Th17
responses in these mice. Interestingly, the levels of
the anti-inflammatory cytokine IL-10 in the superna-
tants of VPAC1 KO cultures were significantly lower
than those in WT cultures, where this cytokine was
highly produced in response to MOG. This cytokine
has been shown to be produced by Th2 and regula-
tory T cells. In addition, the levels of IL-4 (a Th2
cytokine) in our culture supernatants were not detect-
able by ELISA, but we found a significantly diminished
expression of IL-4 mRNA in the MOG-stimulated lymph-
oid cells of immunized VPAC1 KO mice compared to
WT. In summary, the lack of VPAC1 leads to an altered
Th response, with enhanced Th1 and Th17 but reduced
Th2 profiles, and possibly a diminution of Treg cells. In
addition, the ability of Th cells from immunized VPAC1
KO mice to respond to MOG indicate that the mice do
not exhibit a defect in the immunization phase of EAE
and that the resistance in the mutant mice is not likely
due to a compensatory suppression of immunization sec-
ondary to VPAC1 loss.
Impaired immune cell infiltration in the CNS of VPAC1 KO
mice
During the earliest phases of the pathogenesis of EAE,
small numbers of encephalitogenic cells enter the sub-
arachnoid space, where it has been suggested that they
are reactivated by local antigen-presenting cells [41].
They then cross the blood-brain barrier (BBB) and
infiltrate the CNS parenchyma where they initiate an
inflammatory response characterized by the recruit-
ment of increasing numbers of immune cells. Our data
suggest that VPAC1 KO mice are capable of develop-
ing highly reactive lymphocytes in response to EAE
immunization. However, these cells may exhibit de-
fects in their ability to migrate into the CNS or fail to
amplify the inflammatory response. Thus, in addition
to our histopathological studies performed 30 days
post-immunization, we determined by immunofluores-
cence the presence of lymphocytes in the spinal cords
of VPAC1 KO vs. WT mice at a time corresponding to
the peak of inflammation in WT mice (14 days after
immunization) (Fig. 4). We found that, at this time
point, significant numbers of T cells had accumulated
in the meninges and infiltrated the CNS parenchyma
of the WT mice. However, there was no lymphocyte
infiltration in the CNS parenchyma of VPAC1 KO-
immunized mice. Moreover, there were few/absent
lymphocytes in the perivascular areas and in the men-
inges. These data suggest that VPAC1 KO mice may
exhibit a deficit in T cell homing to both the CNS
perivascular/meningeal areas and to subsequent CNS
parenchyma invasion, a phenotype similar to that we
observed in VIP KO mice [17].
Absence of VPAC1 receptors in either T cells or bone
marrow-derived hematopoietic cells does not account for
the lack of full EAE development in the VPAC1 KO mice
The previous experiments suggest that the ameliorated
clinical EAE in VPAC1 KO mice is due to a defect in the
effector phase of the disease rather than impaired
immunization. To corroborate this possibility, we first
performed adoptive transfer studies in which we admi-
nistered WT or VPAC1 KO immune cells from EAE-
immunized mice into WT or VPAC1 KO recipients
(Fig. 5a). We found that WT recipients receiving cells from
WT donors developed EAE with an onset on day ~8, a
peak on days 12–13, and a subsequent recovery phase.
These mice developed a similar EAE clinical course when
receiving cells from MOG-immunized VPAC1 KO mice,
supporting the full encephalitogenic potential of these cells
as suggested by antigen-recall assays. In contrast, when
VPAC1 KO mice received WT cells, they developed only
minor EAE symptoms. Together, the adoptive transfer
studies suggest that lymphocytes from the KO mice main-
tain the potential to induce EAE but that they are not
capable of triggering a full inflammatory response in a
VPAC1-deficient environment.
The adoptive transfer studies indicated that loss of
VPAC1 in encephalitogenic T cells is not sufficient to
explain the EAE resistance of VPAC1 KO mice. Periph-
eral myeloid cells are clearly required to produce full
EAE [42, 43], so it remains possible that VPAC1 loss on
these or other hematopoietic cells explains the EAE
resistance in these mice. To investigate this possibility,
Fig. 4 VPAC1-deficient mice exhibit reduced immune cell infiltration
into the CNS meninges and parenchyma after EAE induction. EAE
was induced in WT and VPAC1 KO mice as described in the “Methods”,
and the spinal cord tissues were obtained on day 14 post-immunization.
Cryostat section were stained by immunofluorescence for CD4 (Alexa
594), laminin (FITC), and nuclei (DAPI). Representative photomicrographs
at ×20 magnification are shown. Results shown are representative of two
independent experiments of n= 3 mice/group
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we performed bone marrow chimera experiments in
which CD45.1 WT mice were γ-irradiated and received
CD45.2 WT or CD45.2 VPAC1 KO bone marrow cells.
Reconstitution analyses indicated that 85–90 % of im-
mune cells were donors derived in recipients. WT→WT
chimeric mice were found to develop chronic EAE with
an onset on days 8–9 and no remission of the disease
(Fig. 5b). WT chimeric mice with a deletion of VPAC1
in the hematopoietic compartment (KO→WT) also
developed EAE in a similar fashion, although the severity
of the disease was slightly, although significantly lower
between days 20 and 25 than that in WT→WT mice.
These results suggest that VPAC1 deficiency in the non-
CNS hematopoietic compartment plays a role but is
minimally responsible for the remarkable resistance to
clinical EAE development found in VPAC1 KO mice.
The expression of chemokines is reduced in the CNS of
MOG-immunized VPAC1 KO vs. WT mice
Our adoptive transfer data suggests that the intrinsic
ability of VPAC1 KO immune cells to enter the CNS is
not defective. We next investigated by real-time RT-PCR
whether or not the expression of chemokines in the
spinal cord is impaired in these mice at the peak of EAE
(Fig. 6). We found that the expression of RANTES/
CCL5, MCP-1/CCL2, and MCP-2/CCL8 and the chemo-
kine receptors CCR1, CCR2, and CCR5 were significantly
reduced in VPAC1 KO mice. In addition, we determined
the expression of MIG/CXCL9, IP-10/CXCL10, and
MIP3-α/CCL20, which are purported to be Th1 (MIG and
IP-10)- and Th17-specific (CCL20) chemokines, and
found then to be also significantly reduced in VPAC1 KO
mice. Similar reductions were found at an earlier time
point (day 5 post-immunization), when clinical EAE has
not yet manifested (Additional file 3: Figure S2). This
could account for the lack of immune infiltration in these
mice and suggests a role for VIP/VPAC1 for chemokine
induction and cell migration. Moreover, these effects were
specific, as we found that the expression of the adhesion
molecules ICAM and VCAM was not reduced in
VPAC1 KO mice, suggesting that VIP/VPAC1 may not
be required for cellular adhesion.
Discussion
VIP, PACAP, and their receptors have been proposed as
potential candidates for the treatment of inflammatory
and autoimmune conditions such as MS. Studies utiliz-
ing specific VPAC1, VPAC2, and PAC1 agonists have
suggested an anti-inflammatory role for all three recep-
tors, although VPAC1 has been implicated as the
principle receptor involved [4]. However, our results in
peptide and receptor KO mice have brought new infor-
mation regarding the roles of the endogenous peptides
in the pathogenesis of EAE and the receptor subtypes
involved. Whereas the neuropeptide PACAP and the
VPAC2 receptor appear to prevail as inhibitors of
inflammation and clinical disease, VIP and VPAC1 re-
ceptors seem to be necessary at some point for EAE
development. This new evidence strongly suggests that
some aspect of EAE could be potentially blocked
pharmacologically with a VPAC1 antagonist. In fact, we
report here that a 2-week pretreatment with a VPAC1
antagonist attenuated the development of the disease.
This is in contrast with previous studies in the context
of multiple models of acute and chronic inflammation
(including EAE), in which a short-term treatment with a
VPAC1 agonist started at the beginning or during on-
going disease was beneficial [28, 30, 44]. Both the length
and the different start points for the treatment might
influence dual actions of VIP/VPAC1. In our studies with
a VPAC1 antagonist treatment, a long-term administration
before EAE induction led to a lack of EAE similar to that
Fig. 5 The expression of VPAC1 in the immune/hematopoietic compartment is not critical for the development of full EAE. Adoptive transfer and
bone marrow chimera studies were performed in order to investigate the contribution of VPAC1 receptor expression in immune/hematopoietic
cells to the resistant phenotype observed in VPAC1 KO mice. a For adoptive transfer experiments, 5 × 106 splenocytes and 5 × 106 lymph node
cells from EAE-immunized WT and VPAC1 KO mice restimulated with MOG in vitro for 3 days were injected i.v. into naïve WT or VPAC1 KO recipients.
The EAE clinical curve of a representative experiment out of three with n = 5 for each group is shown. b In order to generate bone marrow (BM)
chimeric mice, WT mice were γ-irradiated (n = 5 for WT→WT and n = 9 for VPAC1 KO→WT) and received 107 BM cells from either VPAC1 receptor KO
(CD45.2) or WT (CD45.2) mice. Six weeks later, mice were MOG35–55-immunized for EAE induction. *p < 0.05, Student’s t test
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found in VPAC1 KO mice. However, a short-term admin-
istration during the early phases of EAE did not alter the
early EAE course, suggesting that VPAC1 activation dur-
ing this time frame does not regulate immune cell infiltra-
tion. Moreover, in agreement with published studies, we
found that a short-term administration of a VPAC1 agon-
ist during early EAE phases blocked EAE development
(Additional file 2: Figure S1). The dual stimulatory vs.
inhibitory effects of VIP/VPAC1 may depend on different
factors such as their level of expression, their target cellular
activation status, or their interaction with other mediators
present in the microenvironment (i.e., basal vs inflamma-
tory conditions). Variations in the expression of VPAC1
and VPAC2 in immune cells upon exposure to different
stimuli have been described. For example, VPAC1 was
reported to be constitutively expressed in multiple immune
cell types investigated (i.e., T lymphocytes and macro-
phages) and downregulated after cellular stimulation
[45–50]. In contrast, VPAC2 has a low expression in
several cellular subtypes that is increased after cellular
activation [5, 51]. The consequence of the reciprocal regu-
lation of VPAC1 and VPAC2 in immune cells during
inflammation has yet to be determined but could conceiv-
ably play a role in the paradoxical EAE resistance of VPAC1
KO and VPAC1 antagonist-pretreated WT mice.
EAE is a multistep pathology in which two phases
have been characterized: the immunization and the ef-
fector phase. During the immunization phase, the anti-
gen is drained to the lymph nodes located proximal to
the injection site and presented by dendritic cells to
naïve T cells that in turn become encephalitogenic.
Later on, during the effector phase, these cells migrate
to the CNS where they trigger an inflammatory response
involving the further recruitment of increasing numbers
of immune cells as well as the local activation of microglia.
The pathogenesis of EAE is considered to be driven by
both Th1 and Th17 cells, and their hallmark cytokines,
IFNγ and IL-17, are strong activators of the innate arm of
immunity. A possible explanation for the lack of EAE
development in VPAC1 KO mice would be a requirement
for this receptor in the immunization phase of the disease.
However, our results show that cells from VPAC1 KO-
immunized mice were able to respond to MOG in vitro.
Moreover, our results demonstrate stronger Th1 and
Th17 but reduced Th2 responses in these mice. These
results, which agree with the demonstrated ability of
VIP to favor Th2 vs. Th1 responses in vitro and in vivo
[16, 18, 21], are similar to those recently found in
VPAC2-deficient mice, suggesting an involvement of
both receptors on VIP-mediated Th differentiation [33].
Fig. 6 Chemokine and chemokine receptor but not adhesion molecule expressions in the CNS of EAE-immunized mice are reduced in VPAC1 KO
mice. EAE was induced in WT- and VPAC1-deficient mice, and the spinal cords were collected and fresh-frozen in liquid nitrogen at the peak of
EAE (14–15 days later). RNA was extracted and retrotranscribed to cDNA, and the levels of expression of a the lymphocyte chemokines RANTES/
CCL5, MIG/CXCL9 (Th1), IP-10/CXCL10 (Th1), and MIP-3α/CCL20 (Th17); b the monocyte chemokines MCP-1/CCL2 and MCP-2/CCL8; c the
chemokine receptors CCR1, CCR2, and CCR5; and d the adhesion molecules ICAM and VCAM were determined by real-time RT-PCR as
described in the “Methods” sections. Results shown are representative of two independent experiments of n = 5 mice/group. *p < 0.05,
**p < 0.01, ***p < 0.001, ns = not significant; Student’s t test
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Nevertheless, the EAE phenotype in VPAC1 and VPAC2
KO mice is opposite, suggesting that events apart from Th
polarization are differentially mediated by VPAC1 and
VPAC2. Adoptive transfer is a useful experimental ap-
proach as it bypasses the initial phase in which endogen-
ous T cells are exposed to the autoantigen, by injecting
cells from immunized mice that have been reactivated in
vitro [52]. Upon transfer, lymphocytes from VPAC1 KO
mice induced EAE in WT recipients, supporting the nor-
mal development of encephalitogenic T cells in these mice
upon MOG administration. However, cells from WT
mice, which were perfectly capable of inducing the disease
in WT recipients, did not transfer EAE to KO mice. This
suggests that these cells were not capable of migrating to
the CNS, were unable to cross the BBB, or could not be
locally reactivated to exert their effector functions. Our
immunofluorescence results suggest that the former may
be a possibility, since we found very few CD4+ cells in
VPAC1 KO mice directly immunized with MOG. In an
attempt to determine whether or not immune cells are
retained in the lymphoid organs or the peripheral circula-
tion of VPAC1 KO mice, we have measured and com-
pared the numbers of white blood cells and percentages of
lymphocytes and monocytes in WT vs. VPAC1 KO mice
during EAE. We found that the number of lympho-
cytes in the blood of VPAC1 KO mice on day 9 post-
immunization was significantly higher than in WT
mice, which might be due to the inability of these
cells to enter the brain (Additional file 4: Figure S3).
In the lymph nodes, the total number of cells in WT
and VPAC1 KO mice before EAE and at the peak of
the disease were not significantly different (Additional
file 5: Figure S4).
Several in vitro studies have shown a direct effect of
VIP on T cell chemotaxis. A study demonstrated a
chemoattractant activity for VIP on unstimulated and
stimulated T cells, although the effect was less pro-
nounced in the latter [53]. In that study, VIP treatment of
T cells augmented their adhesion to ICAM and VCAM in
vitro. These molecules play an important role in the adhe-
sion of T cells to the endothelium and their subsequent
transmigration. In addition, VIP increased T cell adhesion
to fibronectin, a component of the extracellular matrix,
through which T cells must migrate upon extravasation.
Moreover, VIP increased the production of metallopro-
tease 9 (MMP-9) by the lymphoblastoma T cell line Tsup1
and increased cell migration through a layer of basement
membrane-like Matrigel [54]. In another study, VIP and a
VPAC1 ligand stimulated chemotaxis of human T and B
lymphocytes into micropore filters [55]. Finally, a tran-
scriptomic analysis of VIP-regulated genes in murine
isolated TCD4+ splenic lymphocytes revealed an increased
expression of multiple genes related to homing and migra-
tion upon VIP treatment in vitro concomitant to PMA and
ionomycin activation [56]. Despite these findings, VPAC1
KO immune cells induced EAE upon transfer to WT recip-
ients, suggesting that their intrinsic ability to migrate is not
impaired, and that the EAE-resistant phenotype is
dependent on VPAC1 receptor loss in another cell type. Al-
though it is still possible that the prior ex vivo re-
stimulation of lymphocytes artificially restored this func-
tion, our bone marrow chimera studies, in which the WT
hematopoietic/immune compartment was replaced by that
of VPAC1 mice before EAE induction, also support that
VPAC1 expression in this compartment has little relevance
for the development of full disease. However, it is well
known that microglia are not eliminated by irradiation by
this bone marrow chimera protocol, so it remains possible
that loss of VPAC1 in this hematopoietic cell type explains
much of the EAE resistance of VPAC1 KO mice.
Our data suggests that the absence of VPAC1 may
disrupt the mechanisms involved in the migration of
immune cells into the CNS in EAE. In order for this to
occur, cells must cross the BBB, which has several
molecular and cellular components such as the tight
junctions between the endothelial cells and the astro-
cytic feet or glia limitans. Activation of microglia and
secretion of pro-inflammatory mediators, metallopro-
teases, and chemokines are also necessary in order to
promote cell migration and to amplify the inflamma-
tory response. There is evidence suggesting that these
cell types express VIP/PACAP receptors [57–60], and
acting on them, they could modulate immune cell mi-
gration. The absence of VPAC1 in such cells may
interfere with the entrance of the first T cells into the
CNS or in the subsequent immune cell infiltration
during the amplification step. Among all factors involved
in cell migration during EAE, Arima et al. highlighted a
critical role for IL-6 for the initial entry of immune cells
through the lumbar region of the spinal cord [61]. Inter-
estingly, it has been shown that VIP promotes the secre-
tion of IL-6 by resting macrophages [62], and we found
this cytokine among others to be downregulated in MOG-
immunized VIP and VPAC1 KO mice. Both Arima et al.
and Reboldi et al. [63] have suggested that CCL20 is
necessary in the first immune cell entry into the CNS, and
we also found this chemokine to be reduced in these mice.
Interestingly, the expression of all cytokines and chemo-
kines we measured was decreased in VPAC1 KO mice,
whereas the expression of adhesion molecules was simi-
larly induced in WT and VPAC1 KO mice. The latter
suggest that the defects are specific for the chemokine
system. Whether or not VIP is required for transmigration
of immune cells by modulating the physical architecture
or functioning of the BBB remains to be elucidated.
One of the properties of VIP that might be related to
cell migration is its ability to elicit vasodilation. Other
vasodilatory peptides, such as adrenomedullin, which
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causes vasodilation in the cerebral circulation, have been
suggested to play an important role in the regulation of
specific BBB properties as endothelium-derived auto-
crine/paracrine hormones [64, 65]. Vasodilation is likely
to increase BBB permeability [66]. The vasodilatory
actions of VIP and PACAP in brain arteries have been
demonstrated in the context of migraine. Dilatation of
the intracranial vasculature is considered a putative
trigger factor for the activation of nociceptors, which
has been involved in the pathogenesis of migraine. It has
been shown that administration of VIP or PACAP causes
headache in healthy volunteers, albeit with significantly
less potency of VIP compared to PACAP [67, 68]. Never-
theless, whether or not this general vasodilatory activity
plays a role in immune cell migration across the BBB
remains to be elucidated.
Another report has also described a reduced response of
VPAC1 KO mice to inflammation. In this study, VPAC1
KO mice developed a milder colitis induced with the chem-
ical dextran sodium sulfate (DSS) than WT mice [69]. In
that report, the authors suggested that VIP through VPAC1
signaling may exhibit pro-inflammatory actions through
the induction of Th17 responses or mediating immune cell
migration to the gut. The resistance of VPAC1 KO mice to
inflammatory insult in the DSS colitis and EAE models is
reminiscent of that found in mice deficient in VIP (the
ligand) in EAE and other models of inflammation such
as TNBS-induced colitis and endotoxemia induced by
a lethal dose of LPS, a model of acute inflammation
with no Th1/Th17 implication [34–36]. We have pro-
posed that the reduced inflammation in VIP KO mice
is due, at least partially, to certain defects in the innate
immune response, because peritoneal cells from these
mice produced reduced levels of the pro-inflammatory
cytokines TNFα and IL-6 in response to LPS [35].
Both stimulatory and inhibitory actions for VIP on
these cytokines have been reported in different experi-
mental settings [62, 70, 71]. Nevertheless, whether or
not this is the case in VPAC1-deficient mice remains
to be elucidated. Despite the fact that VIP-VPAC1
could potentially play an active role to promote immune
responses, other possibilities to explain the resistance of
the KO mice for these molecules, such as compensatory
anti-inflammatory mechanisms, cannot be excluded at this
time. Interestingly, this has been shown to be the
case in mice deficient in cortistatin [72]. Despite the
anti-inflammatory actions of this neuropeptide, cortistatin-
deficient mice were paradoxically resistant to EAE develop-
ment, which was found to be associated to basal elevated
circulating glucocorticoids and an anxiety-like behavior.
Conversely, we have not found increased serum cortico-
sterone levels in basal conditions or in response to an acute
stressor in VIP KO mice, although this remains to be eluci-
dated in the context of EAE [73].
Fig. 7 Scheme suggesting potential roles of VPAC1 on EAE. Upon MOG administration, EAE has two phases: the induction or priming phase and
the effector phase. In the induction phase, MOG drains to the local lymph nodes and T cells are activated and polarized towards Th1 and Th17
cells. In the effector phase, these cells migrate to the CNS, where they mount an inflammatory response amplified by immune cell recruitment.
Our data suggests that VPAC1 signaling on non-immune cells or microglia may be required for the effector phase of EAE and may explain the
lack of clinical disease in VPAC1 KO mice or upon pretreatment of WT mice with a VPAC1 antagonist (VPAC1 antago). VPAC1 anti-inflammatory
actions would be prevalent only during ongoing disease, and thus a VPAC1 agonist (VPAC1 ago) administered during this time blocked the dis-
ease. A treatment with a VPAC1 antagonist during ongoing disease during the same time frame post-EAE induction did not prevent and may
have exacerbated the disease. Mice deficient in one of the two VPAC1 ligands, VIP, are also resistant to EAE, whereas PACAP-deficient mice exhibit
exacerbated EAE, implying a critical VIP/VPAC1 interaction that is required for the development of EAE
Abad et al. Journal of Neuroinflammation  (2016) 13:169 Page 11 of 14
Our prior results using KO mice have shown that
VPAC2 receptor and PACAP KO mice developed exac-
erbated EAE as expected, supporting the primarily anti-
inflammatory properties of these endogenous molecules
in untreated mice. Data from pharmacological studies
show that major anti-inflammatory effects of exogen-
ously administered VIP and PACAP in EAE models are
mediated by VPAC1, although a VPAC2 receptor-specific
agonist was shown to be also anti-inflammatory. Con-
versely, VIP and VPAC1 KO mice were resistant to full
EAE development. This unexpected phenotype in VPAC1
receptor-deficient mice suggests a specific requirement of
VIP/VPAC1 interaction required for the full development
of autoimmune inflammation (Fig. 7). While our studies
so far have shown that the administration of a VPAC1
agonist during the initial stages of EAE development
suppressed EAE, it remains to be determined if chronic
administration of a VPAC1 agonist would begin to worsen
EAE, as might be suggested by the EAE resistance of mice
with chronic global loss of VPAC1.
Conclusions
In this study, we have found that the VIP/PACAP recep-
tor VPAC1 is required for the full development of EAE,
as VPAC1 KO mice exhibited an unexpectedly but strik-
ingly ameliorated clinical course of the disease. The facts
that (1) in vitro, antigen-rechallenged lymph node cells
from VPAC1 KO mice respond strongly to MOG, (2)
VPAC1 KO lymph node cells induce EAE upon transfer
to WT mice, and (3) bone marrow chimeric VPAC1
KO→WT mice develop full EAE suggest that the
deficient ability of VPAC1 KO mice to develop EAE is
not due to impairments in the immunization phase of
the disease. Our study suggests that VPAC1 may play
different roles in the pathogenesis of EAE, i.e., permissive
in the early stages vs. anti-inflammatory if pharmacologic-
ally targeted during ongoing inflammation (Fig. 7). Thus,
the use of agonists vs. antagonists of VPAC1 should be
carefully examined to achieve maximum beneficial effects
in diseases such as MS.
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